Expert Discusses Best Practices for Managing Breast Cancer–Related ToxicitiesMarch 14th 2022
Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.
Sacituzumab Govitecan Bests Chemotherapy by Improving Progression-Free Survival in HR+ Metastatic Breast CancerMarch 11th 2022
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer achieved statistically significantly improvements in progression-free survival after receiving sacituzumab govitecan.
Quality Oncology Care: Discussing Fertility Preservation for Patients With Breast CancerMarch 7th 2022
At a presentation during the 39th Annual Miami Breast Cancer Conference, Lindsay Kroener, MD, highlighted key components related to fertility preservation for patients with breast cancer.
Eribulin Elicits Promising 2-Year Overall Survival in Pretreated Metastatic Breast CancerMarch 6th 2022
Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.
HER-2 Directed Therapies Making Waves in Early-Stage and Metastatic Breast CancerFebruary 17th 2022
A City of Hope expert underscores the benefit of using antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint blockade in early-stage and metastatic breast cancer.
Bioimpedance Spectroscopy Is a Better Predictor of Chronic Lymphedema Vs Tape MeasurementFebruary 6th 2022
Patients who underwent surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.
Trastuzumab Deruxtecan Receives Priority Review for Select Patients With HER2+ Metastatic Breast CancerJanuary 18th 2022
A supplemental biologics license application has been granted to trastuzumab deruxtecan-nxki for the treatment of adult patients with select HER2-positive breast cancer.
Patients With HER2+ Metastatic Breast Cancer Experience Consistent PFS Benefit With Trastuzumab DeruxtecanJanuary 14th 2022
An expert discusses the implications of a subgroup analysis of the DESTINY-BREAST03 trial, which highlighted the efficacy of trastuzumab deruxtecan in HER2-positive metastatic breast cancer.
Patients With HER2+ Breast Cancer and Brain Metastases Achieve Better OS With Tucatinib Triplet RegimenJanuary 9th 2022
A triplet regimen of tucatinib, trastuzumab, and capecitabine helped patients with HER2-positive metastatic breast cancer and brain metastases live longer with reduced disease progression compared with trastuzumab and capecitabine alone.
Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast CancerDecember 28th 2021
Updates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.
New Data Suggest that Olaparib-Related Adverse Events are Manageable in High-Risk Early Breast CancerDecember 12th 2021
Findings presented at the 2021 San Antonio Breast Cancer Symposium suggest that Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with breast cancer.
Black Patients With Breast Cancer Experience Higher Rate of Treatment Modifications or DiscontinuationsDecember 10th 2021
Treatment modifications were inconsistent among White and Black patients with breast cancer. However, the use of a multiscale biophysical modeling platform may be useful in informing treatment modification decisions.
Palbociclib Shows Clinical Benefit in Black and Hispanic Patients with HR+ Breast CancerDecember 9th 2021
Findings from a pooled efficacy and safety analysis support the use of palbociclib plus endocrine therapy in patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer.
Aromatase Inhibitors Linked to Lower Incidence of Recurrence in Premenopausal ER+ Breast CancerDecember 9th 2021
Aromatase inhibitors were revealed to be more effective than tamoxifen in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
Targeted Therapy With Multigene Sequencing Shows Superior PFS Vs Chemotherapy in Metastatic Breast CancerDecember 8th 2021
Patients who received matched targeted therapy specific to their genomic alteration, as identified through multigene sequencing, experienced significantly improved progression-free survival.